1. Epigenetics
  2. Epigenetic Reader Domain
  3. Menin-MLL-IN-37

Menin-MLL-IN-37 是一种具有口服活性的 Menin-MLL 蛋白复合物抑制剂,其 IC50 为 820.50 nM。Menin-MLL-IN-37 可破坏 meninMLL 蛋白之间的相互作用。Menin-MLL-IN-37 可诱导急性髓系白血病细胞分化,并选择性抑制 MLL 重排型及 DNMT3A/NPM1 突变型白血病细胞的增殖。Menin-MLL-IN-37 可用于急性髓系白血病 (AML) 的相关研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Menin-MLL-IN-37

Menin-MLL-IN-37 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML)[1].

IC50 & Target[1]

Menin-MLL

820.50 nM (IC50)

体外研究
(In Vitro)

Menin-MLL-IN-37 (Compound A13) 可强效抑制 MLL 重排 (MV4-11、MOLM-13)、DNMT3A/NPM1 突变 (OCI-AML3) 及其他白血病细胞系 (THP-1, HL-60, K562) 的增殖,其 IC50 值分别为 0.379、0.838、0.763、1.618、1.179 和 2.653 μM[1]
Menin-MLL-IN-37 (1-2 μM; 7 days) 可诱导 MV4-11 和 MOLM-13 白血病细胞分化,导致 CD11b 表面表达水平升高[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay[1]

Cell Line: MV4-11, MOLM-13 leukemia cell lines
Concentration: 1000 nM, 2000 nM
Incubation Time: 7 days
Result: Induced a significant increase in the percentage of CD11b-positive cells in MV4-11 cell line.
Induced a significant increase in the percentage of CD11b-positive cells in MOLM-13 cell line.
药代动力学
(Parmacokinetics)
Species Dose Route Tmax T1/2 Cmax AUC0-t AUC0-∞ MRT0-t Vz/F CL/F
Mice[1] 20 mg/kg i.g. 1.67 h 2.43 h 537.00 ng/mL 2241.09 ng·h/mL 2379.51 ng·h/mL 3.59 h 30499.24 mL/kg 147.32 mL/min/kg
体内研究
(In Vivo)

Menin-MLL-IN-37 (Compound A13) (20 mg/kg;灌胃;单剂量) 在小鼠中展现出良好的口服药代动力学特性 ,其吸收迅速且生物利用度高[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice[1]
Dosage: 20 mg/kg
Administration: I.g.; Blood samples were then collected at 0.25, 0.5, 1, 2, 4, 8, and 24 h post-dose
Result: Displayed favorable oral pharmacokinetic properties (Tmax=1.67 h, AUC=2241 ng h/mL), characterized by rapid absorption and high bioavailability, demonstrating its potential as a therapeutic agent
分子量

638.77

Formula

C29H37F3N6O3S2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Menin-MLL-IN-37
目录号:
HY-181690
需求量: